A clinical trial update dated September 4, 2026 reports on a Phase 2 study titled "Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss."
The study, registered as NCT07446998, is listed with a status of active, not recruiting. This means enrollment has closed but the trial is still ongoing.
According to the listing, the study is designed to evaluate total body weight, physical function, and safety outcomes in patients who are being treated with a GLP-1 receptor agonist for weight loss, with enobosarm added to that regimen. The trial is identified as a proof-of-concept study and is registered at the Phase 2 stage.
No results have been posted as part of this update, and no efficacy or safety findings are described. This brief reflects only the trial's registered status and design as stated in the record, not outcomes.
This update pertains to glucagon-related research context as tracked alongside GLP-1 receptor agonist therapies, and glucagon itself remains an approved compound. Readers interested in background on glucagon can consult the compound overview for further context.